 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C18H22N2 |
| Molar mass | 266.388 g·mol−1 |
| 3D model (JSmol) | |
| |
Mezepine is a tricyclic antidepressant (TCA) that was never marketed. [1]
Tricyclic antidepressants (TCAs) are a class of medications that are used primarily as antidepressants. TCAs were discovered in the early 1950s and were marketed later in the decade. They are named after their chemical structure, which contains three rings of atoms. Tetracyclic antidepressants (TeCAs), which contain four rings of atoms, are a closely related group of antidepressant compounds.
Tricyclics are chemical compounds that contain three interconnected rings of atoms.
Alfetamine, or alpha-allyl-phenethylamine, is a chemical compound of the phenethylamine family. It was briefly investigated as a possible antidepressant in the early 1970s. Its activity profile was said to be very similar to imipramine and amitriptyline, two tricyclic antidepressants.
Tricyclic antidepressant overdose is poisoning caused by excessive medication of the tricyclic antidepressant (TCA) type. Symptoms may include elevated body temperature, blurred vision, dilated pupils, sleepiness, confusion, seizures, rapid heart rate, and cardiac arrest. If symptoms have not occurred within six hours of exposure they are unlikely to occur.
Quinupramine is a tricyclic antidepressant (TCA) used in Europe for the treatment of depression.
Dimetacrine, also known as dimethacrine and acripramine, is a tricyclic antidepressant (TCA) used in Europe and formerly in Japan for the treatment of depression. It has imipramine-like effects; though, in a double-blind clinical trial against imipramine, dimetacrine was found to have lower efficacy in comparison and produced more weight loss and abnormal liver tests. Little is known about the pharmacology of dimetacrine, but it can be inferred that it acts in a similar manner to other TCAs. If this is indeed the case, dimetacrine may induce severe cardiac toxicity in overdose.
Noxiptiline, also known as noxiptyline and dibenzoxine, is a tricyclic antidepressant (TCA) that was introduced in Europe in the 1970s for the treatment of depression. It has imipramine-like effects, acting as a serotonin and norepinephrine reuptake inhibitor, among other properties. Of the TCAs, noxiptiline has been described as one of the most effective, rivaling amitriptyline in clinical efficacy.
Intriptyline is a tricyclic antidepressant (TCA) that was never marketed.
Azepindole (McN-2453) is a tricyclic compound with antidepressant and antihypertensive effects that was developed in the late 1960s but was never marketed.
Ketipramine (G-35,259), also known as ketimipramine or ketoimipramine, is a tricyclic antidepressant (TCA) that was tested in clinical trials for the treatment of depression in the 1960s but was never marketed. It differs from imipramine in terms of chemical structure only by the addition of a ketone group, to the azepine ring, and is approximately equivalent in effectiveness as an antidepressant in comparison.
Tampramine (AHR-9,377) is a tricyclic antidepressant (TCA) which was developed in the 1980s but was never marketed. Despite being a TCA, it acts as a selective norepinephrine reuptake inhibitor and has negligible affinity for adrenergic, histaminergic, and muscarinic receptors. It was found to be effective in the forced swim test (FST) model of depression in animal studies but is not known to have ever been trialed in humans.
Fluotracen (SKF-28,175) is a tricyclic drug which possesses dual antidepressant and antipsychotic activity. This profile of effects is similar to that of related agents like amoxapine, loxapine, and trimipramine which may also be used in the treatment of both depression and psychosis. It was believed that such duality would be advantageous in the treatment of schizophrenia, as depression is often comorbid with the disorder and usual antipsychotics often worsen such symptoms. In any case, however, fluotracen was never marketed.
Tienopramine is a tricyclic antidepressant (TCA) which was never marketed. It is an analogue of imipramine where one of the benzene rings has been replaced with a thiophene ring.
Mariptiline (EN-207) is a tricyclic antidepressant (TCA) which was developed in the early 1980s, but was never marketed.
Naranol (W-5494A) is a drug with a tricyclic-like structure. It was synthesized in the late 1960s, and was reported to have antidepressant, anxiolytic, and antipsychotic properties, but was never marketed.
Enprazepine is a tricyclic antidepressant (TCA) which was never marketed.
Depramine, also known as balipramine (BAN) and as 10,11-dehydroimipramine, is a tricyclic antidepressant (TCA) which was never marketed.
Amezepine is a tricyclic antidepressant (TCA) which was never marketed.
Dibenzoxepin, or dibenz[b,e]oxepin, is a tricyclic compound. It is the parent structure of certain drugs such as the tricyclic antidepressant doxepin and the analgesic fluradoline. The former is the only tricyclic antidepressant that is a dibenzoxepin.
